SEC 13F Intelligence

Managers / Q4 2024 · view latest →

Octagon Capital Advisors LP

CIK 0001839435 · 654 MADISON AVENUE, 21ST FLOOR, NEW YORK, NY, 10065 · 212-369-2829

Reported Value
$608M
Q4 2024
Positions
33
Filings on Record
23
2019–present window
Filed
Feb 14, 2025
original filing

Summary

Octagon Capital Advisors LP reported $608M in U.S.-listed holdings across 33 positions for Q4 2024.

Its largest position, APLSUSD, represents 15.8% of the portfolio.

Compared with Q3 2024, the fund opened 7 new positions and exited 17.

Portfolio Metrics

Turnover
+23.9%
vs prior filed quarter
Top-10 Concentration
+60.5%
share of reported value
Largest Position
+15.8%
Apellis Pharmaceuticals
New / Exited
7 / 17
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $288MQ4 ’20Q1 ’21: $265MQ2 ’21: $483MQ3 ’21: $406MQ3 ’21Q4 ’21: $514MQ1 ’22: $463MQ2 ’22: $375MQ2 ’22Q3 ’22: $579MQ4 ’22: $642MQ1 ’23: $695MQ1 ’23Q2 ’23: $719MQ3 ’23: $651MQ4 ’23: $625MQ4 ’23Q1 ’24: $834MQ2 ’24: $636MQ3 ’24: $643MQ3 ’24Q4 ’24: $608MQ1 ’25: $517MQ2 ’25: $456MQ2 ’25Q3 ’25: $660MQ4 ’25: $824MQ1 ’26: $904MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 82.3%ADR: 10.3%Other: 7.3%Equity WRT: 0.1%
  • Common Stock · 82.3% · $500M
  • ADR · 10.3% · $62M
  • Other · 7.3% · $45M
  • Equity WRT · 0.1% · $830,814

Quarter-over-Quarter Changes full breakdown →

vs Q3 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SRRKSCHOLAR ROCK HLDG CORPNEW+488.0K488.0K+$21M$21M
MERUS N VNEW+308.0K308.0K+$13M$13M
ERASERASCA INCNEW+5.14M5.14M+$13M$13M
SNDXSYNDAX PHARMACEUTICALS INCNEW+904.0K904.0K+$12M$12M
4XC1KALVISTA PHARMACEUTICALS INCNEW+1.37M1.37M+$12M$12M
ALLOVIR INCNEW+11.21M11.21M+$5M$5M
ATYRATYR PHARMA INCNEW+900.0K900.0K+$3M$3M
NGNENEUROGENE INCADDED+288.0K303.0K+$6M$7M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2024

30 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1APLSUSDAPELLIS PHARMACEUTICALS INChistory →COM15.79%$96M3.01M
2AVBPARRIVENT BIOPHARMA INChistory →COM9.03%$55M2.06M
3DNTHDIANTHUS THERAPEUTICS INChistory →COM7.57%$46M2.11M
4260CENTESSA PHARMACEUTICALS PLChistory →SPONSORED ADS5.49%$33M1.99M
5VRNAVERONA PHARMA PLChistory →SPONSORED ADS4.37%$27M571.3K
6NUVBNUVATION BIO INCCOM CL A · *W EXP 02/10/2024.16%$25M9.52M
7IM8NINSMED INChistory →COM PAR3.77%$23M332.0K
8COGTCOGENT BIOSCIENCES INChistory →COM3.55%$22M2.76M
9SRRKSCHOLAR ROCK HLDG CORPhistory →COM3.47%$21M488.0K
10BRD1EURMIND MEDICINE MINDMED INChistory →COM NEW3.46%$21M3.02M
11OCULOCULAR THERAPEUTIX INChistory →COM3.41%$21M2.42M
12TSHATAYSHA GENE THERAPIES INChistory →COM SHS2.97%$18M10.45M
13VRDNVIRIDIAN THERAPEUTICS INChistory →COM2.74%$17M870.0K
14GOSSGOSSAMER BIO INChistory →COM2.73%$17M18.35M
15DYNDYNE THERAPEUTICS INChistory →COM2.59%$16M668.0K
16PHARVARIS N VCOM2.45%$15M778.0K
17CRBPCORBUS PHARMACEUTICALS HLDGShistory →COM NEW2.17%$13M1.11M
18MERUS N VCOM2.13%$13M308.0K
19ERASERASCA INChistory →COM2.12%$13M5.14M
20BBIOBRIDGEBIO PHARMA INChistory →COM1.99%$12M441.6K
21SNDXSYNDAX PHARMACEUTICALS INChistory →COM1.97%$12M904.0K
224XC1KALVISTA PHARMACEUTICALS INChistory →COM1.91%$12M1.37M
23UNICYCIVE THERAPEUTICS INCCOM1.31%$8M10.00M
24RGLSREGULUS THERAPEUTICS INChistory →COM1.26%$8M4.85M
25CATXPERSPECTIVE THERAPEUTICS INChistory →COM NEW1.21%$7M2.30M
26NGNENEUROGENE INChistory →COM1.14%$7M303.0K
27ALLOVIR INCCOM0.78%$5M11.21M
28ATYRATYR PHARMA INCCOM NEW0.54%$3M900.0K
29HELIX ACQUISITION CORP IICL A ORD SHS0.43%$3M250.0K
30MERSANA THERAPEUTICS INCCOM0.23%$1M992.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$904M29May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$824M27Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$660M27Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$456M30Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$517M35May 16, 2025RESTATEMENTchanges · EDGAR ↗
Q4 2024$608M33Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$643M42Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$636M47Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$834M57May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$625M33Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$651M40Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$719M41Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$695M36May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$642M32Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$579M35Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$375M20Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$463M24May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$514M28Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$406M30Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$483M34Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$265M28May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$288M31Feb 16, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.